CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting-Reference-Cited by-同舟云学术

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

Published:2023-08-03 Issue:1 Volume:16 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Liu Xinyuan,Zhao Juanjuan,Guo Xiangqian,Song Yongping

Abstract

AbstractMultiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20+ NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023).

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

https://link.springer.com/content/pdf/10.1186/s13045-023-01488-4.pdf

Reference13 articles.

1. Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Husser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umana P. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24(19):4785–97.

2. Wang C, Liu Y. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH annual meeting. J Hematol Oncol. 2023;16(1):20.

3. Dickinson M, Viardot A, Marks R, Topp MS, Morschhauser F, Jacobs B, Tani M, Bosch F, Esteban D, Cordoba R, Kaufman D, Wu C, Humphrey K, Baumlin P, Barrett M, Qayum N, Pinto A. Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study. J Clin Oncol. 2023;41(16_suppl):7549–7549.

4. Falchi L, Carlo-Stella C, Morschhauser F, Hutchings M, Bachy E, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, Salar A, Brody J, Leppä S, Mulvihill E, Lundberg L, Relf J, Xie Y, Bottos A, Humphrey K, Dickinson M. Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study. J Clin Oncol. 2023;41(16_suppl):7550–7550.

5. Bock AM, Nowakowski GS, Wang Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. Curr Treat Opt Oncol. 2022;23(2):155–70.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges;Molecular Biotechnology;2024-09-02

2. A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin’s lymphoma;Journal of Nanobiotechnology;2024-08-10

3. A general approach to reduce off-target radioactivity in vivo via Tetrazine-Knock-Out (TKO);2024-06-02

4. Bispecific and multispecific antibodies in oncology: opportunities and challenges;Nature Reviews Clinical Oncology;2024-05-31

5. Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer;Frontiers in Oncology;2024-04-30